Triple

T17377863
Position Surface form Disambiguated ID Type / Status
Subject Cambridge Antibody Technology E422486 entity
Predicate successorOrganization P78 FINISHED
Object MedImmune NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: MedImmune | Statement: [Cambridge Antibody Technology, successorOrganization, MedImmune]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: MedImmune
Context triple: [Cambridge Antibody Technology, successorOrganization, MedImmune]
  • A. MedImmune chosen
    MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
  • B. Genmab
    Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
  • C. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • D. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • E. AbbVie
    AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d889d6535c81908be333c01deaec4e completed April 10, 2026, 5:25 a.m.
NER Named-entity recognition batch_69e43a6ea56c8190b56d966ccf2c91f7 completed April 19, 2026, 2:14 a.m.
Created at: April 10, 2026, 5:45 a.m.